Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfs230D1-EPA + AS01
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Pfs230D1-EPA + AS01 is an investigational malaria transmission-blocking vaccine (TBV) candidate developed by the National Institute of Allergy and Infectious Diseases (NIAID). It consists of the recombinant first domain of the Plasmodium falciparum gamete surface protein Pfs230 (Pfs230D1) chemically conjugated to a detoxified Pseudomonas aeruginosa ExoProtein A (EPA) carrier protein, formulated with GlaxoSmithKline's (GSK) liposome-based adjuvant system AS01. The vaccine is designed to elicit antibodies against Pfs230, which are ingested by mosquitoes during a blood meal. In the presence of human complement, these antibodies target and lyse the extracellular gametes of P. falciparum in the mosquito midgut, thereby blocking parasite development and preventing transmission to other humans. It has been evaluated in Phase 1 and Phase 2 clinical trials in malaria-endemic regions such as Mali.
- Other names
- Pfs230D1-EPA/AS01Pfs230D1M-EPA + AS01Pfs230D1M-EPA/AS01
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Pfs230D1-EPA + AS01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfs230D1-EPA + AS01.